跳至主要内容
临床试验/NCT01496638
NCT01496638进行中(未招募)不适用

How Should Coronary Artery Stenoses With Significant Side Branch be Stented? A Strategy of Stenting Both Main Vessel and Side Branch Compared to a Strategy of Stenting the Main Vessel and Only Stenting the Side Branch if Necessary.

Evald Hoej Christiansen2 个研究点 分布在 1 个国家目标入组 450 人开始时间: 2008年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
450
试验地点
2
主要终点
Combined endpoint of: Cardiac death, non-index procedure related myocardial infarction or target lesion revascularisation

研究概览

简要总结

How should coronary artery stenoses with significant side branch be stented?

A strategy of stenting both main vessel and side branch compared to a strategy of stenting the main vessel and only stenting the side branch if necessary.

The 2-stent strategy is superior to the 1-stent strategy regarding occurrence of cardiac death, non-procedure related myocardial infarction and re-revascularization with percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG).

详细描述

Design:

  • Randomised open multicentre trial.

Patients:

  • Number 450.

Randomisation:

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Stable or unstable angina pectoris or silent angina pectoris.
  • Genuine bifurcation lesion ( Medina type 1,1,1 or 1,0,1 or 0,1,1)
  • Lesion of "LAD/diagonal", "Cx/obtuse marginal", "RCA-PDA/posterolateral branch" or "LM/Cx/LAD".
  • Diameter of main vessel by visual estimate >3.0 mm.
  • Diameter of side branch by visual estimate >2.75 mm.
  • Signed informed consent.

排除标准

  • ST-elevation infarction within 24 hours.
  • Side branch lesion length >15 mm.
  • Expected survival < 1 year.
  • S-creatinine >200 µmol/l.
  • Allergy to Aspirin, Clopidogrel or Ticlopidine.
  • Allergy to Sirolimus.

结局指标

主要结局

Combined endpoint of: Cardiac death, non-index procedure related myocardial infarction or target lesion revascularisation

时间窗: After 6 months

次要结局

  • MACE (cardiac death, non-index procedure related myocardial infarction, stent thrombosis or target lesion revasculation)(During admission, after 1, 24, 36 and 60 months.)
  • Non-index procedure related myocardial infarction during the admission.(After 1, 6, 24, 36 and 60 months.)
  • Stent thrombosis.(During admission, after 1, 6, 24, 36 and 60 months.)
  • target lesion revascularisation.(During admission, after 1, 6, 24, 36 and 60 months.)
  • Index procedure related myocardial infarction based on biomarkers (CK-MB mass, TNT/TNI(During hospital period, 1, 8, 24, 36 and 60 months)
  • Total mortality(During admission, after 1, 6, 24, 36 and 60 months and 10 years.)
  • CCS angina class(After 6, 8, 24, 36 and 60 months.)
  • Cardiac death.(During the admission, after 1, 6, 24, 36 and 60 months.)
  • target vessel revascularisation.(During admission, after 1, 6, 24, 36 and 60 months.)

研究者

发起方
Evald Hoej Christiansen
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Evald Hoej Christiansen

MD

Aarhus University Hospital Skejby

研究点 (2)

Loading locations...

相似试验